Skip to main content

Table 1 Association between B3GNT6 level and clinicopathological factors from dataset GSE39582

From: Downregulation of B3GNT6 is a predictor of poor outcomes in patients with colorectal cancer

Variables Testing cohort (n=443) Validating cohort (n=123)
High (n=170) Low (n=273) p value High (n=49) Low (n=74) p value
Age
 ≥65 101 166 0.7351 35 52 0.8901
 <65 69 106   14 22  
 Unavailable 0 1   0 0  
Gender
 Male 90 147 0.8527 32 41 0.2738
 Female 80 126   17 33  
Stage
 I-II 84 137 0.9321 28 48 0.3882
 III-IV 82 136   21 26  
T stage
 T1-T2 21 26 0.3574 2 11 0.0625
 T3-T4 145 239   43 59  
 Unavailable 4 8   4 4  
Lymph node metastasis
 Absent 88 142 0.8803 26 46 0.3906
 Present 76 119   19 24  
 Unavailable 6 12   4 4  
Distant metastasis
 Absent 150 226 0.1474 40 66 0.3078
 Present 16 38   4 3  
 Unavailable 4 9   5 5  
Tumor Location
 Distal 96 171 0.1971 27 48 0.2772
 Proximal 74 102   22 26  
MMR
 dMMR 18 43 0.1222 5 9 0.6202
 pMMR 139 209   41 55  
 Unavailable 13 21   3 10  
CIMP status
 − 111 195 0.1855 38 61 0.4994
 + 33 41   8 9  
 Unavailable 26 37   3 4  
CIN status
 negative 41 41 0.0205 17 11 0.0059
 positive 98 176   25 55  
 Unavailable 31 56   7 8  
tp53 mutation
 Mutated 51 84 0.9483 20 35 0.2642
 Wild type 42 68   24 27  
 Unavailable 77 121   5 12  
Kras mutation
 Mutated 84 88 0.0002 20 25 0.496
 Wild type 78 174   29 47  
 Unavailable 8 11   0 2  
Braf mutation
 Mutated 19 25 0.4532 4 3 0.3401
 Wild type 130 218   44 69  
 Unavailable 21 30   1 2  
  1. MMR mismatch repair, dMMR mismatch repair-deficient, pMMR mismatch repair-proficient, CIMP CpG island methylator phenotype, CIN chromosome instability